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Controversies in cardiovascular medicine
Atrial fibrillation in heart failure:
what should we do?
Dipak Kotecha1,2* and Jonathan P. Piccini3
1Institute of Cardiovascular Science, University of Birmingham, Birmingham, UK; 2Monash Centre of Cardiovascular Research and Education in Therapeutics, Monash University,
Melbourne, Australia; and 3Duke Center for Atrial Fibrillation, Clinical Cardiac Electrophysiology, Duke University Medical Center, Durham, USA
Received 6 July 2015; revised 25 August 2015; accepted 7 September 2015
Heart failure (HF) and atrial fibrillation (AF) are two conditions that are likely to dominate the next 50 years of cardiovascular (CV) care. Both
are increasingly prevalent and associated with high morbidity, mortality, and healthcare cost. They are closely inter-related with similar risk
factors and shared pathophysiology. Patients with concomitant HF and AF suffer from even worse symptoms and poorer prognosis, yet evi-
dence-based evaluation and management of this group of patients is lacking. In this review, we evaluate the common mechanisms for the de-
velopment of AF in HF patients and vice versa, focusing on the evidence for potential treatment strategies. Recent data have suggested that
these patients may respond differently than those with HF or AF alone. These results highlight the clear clinical need to identify and treat ac-
cording to best evidence, in order to prevent adverse outcomes and reduce the huge burden that HF and AF are expected to have on global
healthcare systems in the future. We propose an easy-to-use clinical mnemonic to aid the initial management of newly discovered concomitant
HF and AF, the CAN-TREAT HFrEF + AF algorithm (Cardioversion if compromised; Anticoagulation unless contraindication; Normalize fluid
balance; Target initial heart rate ,110 b.p.m.; Renin–angiotensin–aldosterone modification; Early consideration of rhythm control; Advanced
HF therapies; Treatment of other CV disease).
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Introduction
Heart failure (HF) and atrial fibrillation (AF) were predicted to become
epidemics of the 21st century,1 in part due to increased longevity and
the success in reducing overall cardiovascular (CV) mortality. Both
conditions are increasingly prevalent, with spiralling cost to healthcare
services globally.2–4 The incidence of AF is also predicted to double
over the next 20 years,5,6 with expectations of 120–215 000 new cases
per year by 2030 in Europe alone.7 Rates of HF in a global AF registry
were 33% in paroxysmal, 44% in persistent and 56% in permanent AF.8
Thus, the combination of these two conditions will have a dramatic
impact on healthcare and require a refocusing of CV care.
The pathophysiology and risk factors for HF and AF are closely
aligned, and affected patients are usually elderlywith a significant burden
of comorbidity.8,9 Atrial fibrillation is both a cause and consequence of
HF, with complex interactions leading to impairment of systolic and
diastolic function not present in sinus rhythm. Atrial fibrillation is asso-
ciated with a three-fold increased risk of incident HF.10 Vice versa, the
structural and neurohormonal changes in HF make the development
and progression of AF muchmore likely,11 both in heart failure with re-
duced ejection fraction (HFrEF) and preserved ejection fraction
(HFpEF). Regardless of which comes first, patients with concomitant
HF and AF have significantly worse prognosis.12,13 Given the poor out-
comes associated with HF and AF, finding effective therapies for these
patients is of paramount importance but also challenging—treatments
shown to be effective in one or other of these conditions alone have
also been observed to have efficacy or safety concerns in patients
with HF and AF combined.14,15 In this review, we summarize the
mechanisms and inter-relationship of HF and AF, and provide a
state-of-the-art synopsis on optimal management, considering
how best to combine therapies and the evidence-base supporting
their use.
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Mechanisms and pathophysiology
of atrial fibrillation in heart failure
Heart failure and AF share risk factors and common pathophysiologic
processes (see Figure 1). Hypertension, smoking, obesity, diabetes, re-
nal impairment, sleep apnoea, and coronary artery disease are all asso-
ciated with an increased risk of developing both HF and AF.16 In HF,
neurohormonal imbalance and activation of the renin–angiotensin–
aldosterone system (RAAS) leads to maladaptive physiological
changes including increased filling pressures and afterload. These can
lead to increased left atrial stretch and fibrosis, contributing to the de-
velopment of conduction abnormalities and facilitating the initiation
andmaintenance of AF.17–21 The renin–angiotensin–aldosterone sys-
tem also directly contributes to proarrhythmic remodelling, with
angiotensin II causing atrial fibrosis and anisotropic conduction.22 Pa-
tients with HF also demonstrate altered calcium handling and calcium
overload, which can lead to after-depolarizations and arrhythmia.23
Atrial fibrillation can promote the development of HF by a num-
ber of establishedmechanisms. Loss of atrial systole in AF impairs LV
filling and can decrease cardiac output by up to 25%, particularly in
patients with diastolic dysfunction.24 Irregular and/or rapid ventricu-
lar conduction in AF can lead to LV dysfunction and in some
patients, a tachycardia-induced cardiomyopathy.24,25 Restoration
of sinus rhythm increases stroke volume and LV emptying even
before contractility improves,26 explaining why some patients with
HF gain rapid haemodynamic improvement with cardioversion.
Prevention of atrial fibrillation
in heart failure (and heart failure
in atrial fibrillation)
In the Framingham study, 41% of patients with AF and HF developed
HF first, 38% developed AF first, and in the remaining 21% AF and
HF occurred at the same time.12 While there are no therapies
proven to prevent the risk of incident HF in patients with established
AF, the treatment of modifiable CV risk factors (especially hyperten-
sion), effective rate control and the diagnosis and treatment of asso-
ciated comorbidities (e.g. sleep apnoea) would seem to be sensible
interventions.
What about preventing AF in patients with known HF?
Meta-analysis of RCTs suggests that angiotensin converting enzyme
inhibitors (ACEi) and angiotensin receptor blockers (ARBs) reduce
the risk of incident AF,27 with RR of 0.79 (95% CI 0.62–1.00) and
0.78 (95% CI 0.66–0.92), respectively.28 Data from the Candesartan
in Heart failure-Assessment of Reduction in Mortality and morbidity
program (CHARM) show that ARBs can decrease the risk of new-
onset AF in patients with HFrEF and HFpEF.29 In the b-blocker vs.
placebo trials in HFrEF with baseline sinus rhythm, allocation to
b-blockers was associated with a significant reduction in the ad-
justed odds of incident AF (odds ratio 0.67; 95% CI 0.57–0.79).14
In a small analysis pointing towards the potential benefits of perso-
nalized therapy in patients with HF and AF,30 HF patients who were
homozygotes for b1 adrenergic receptor 389 Arginine had a 74%
reduction in new-onset AF (95%CI 43–88%) when treated with bu-
cindolol vs. placebo.31
Management of concomitant
heart failure and reduced ejection
fraction and atrial fibrillation
Currently, clinicians often manage patients with combined HFrEF
and AF by focusing on particular therapeutic aspects that have an
evidence-base in one or other of these conditions (see Figure 2). Re-
searchers have started to investigate if treatment efficacy differs in
patients with concomitant disease, but at present these data are lim-
ited. In this section, we summarize the evidence-base for common
Figure 1 Shared and synergistic mechanisms in heart failure and atrial fibrillation. There is a cycle of interdependence between heart failure and
atrial fibrillation and each makes the other more likely to occur. RAAS, renin–angiotensin–aldosterone system.
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treatment modalities and suggest a simple clinical mnemonic for the
initial management of newly diagnosed concomitant HF and AF. The
CAN-TREAT HFrEF + AF algorithm (see Figure 3) distinguishes the
management of these patients from those with sinus rhythm. The
presence of haemodynamic instability should be treated with urgent
cardioversion (C). Anticoagulation (A) should be instituted to pre-
vent thromboembolism, and diuretic therapy to normalize (N) fluid
balance and reduce symptoms of HF. Subsequent therapy should
target (T) an initial heart rate ,110 b.p.m. and initiate RAAS antag-
onism (R), though with limited data on efficacy (see details below).
Early (E) rhythm control in patients with symptoms refractory to
rate control, and consideration of advanced (A) HF therapies should
follow (e.g. cardiac resynchronization therapy), with aggressive
treatment (T) of other concomitant CV disease, particularly ischae-
mia and hypertension.
Anticoagulation
Stroke is the most feared complication of AF, most commonly due
to embolization of thrombus from the left atrial appendage. Throm-
bus formation in AF fulfils Virchow’s triad of a prothrombotic milieu,
stagnant blood flow and endothelial dysfunction. Anticoagulation
with vitamin K antagonists (VKA; e.g. warfarin) or non-VKA anticoa-
gulants (NOACs) prevent 2/3 of ischaemic strokes in AF pa-
tients.32,33 Reduced left ventricular ejection fraction (LVEF) is
independently associated with stroke,34 and the combination of
HFrEF with AF doubles the risk of stroke comparedwith AF alone.35
Although no trials have investigated this specific population, indirect
sub-group data from the NOAC RCTs suggest the effect of anticoa-
gulation for AF is similar in patients with concomitant HF.36–40With
the combination of higher stroke risk and effective therapy, anticoa-
gulation is essential in all patients with HF and AF that do not have an
Figure 2 Major priorities of management in patients with heart failure and reduced ejection fraction and those with atrial fibrillation. HFrEF,
heart failure with reduced ejection fraction; AF, atrial fibrillation; CV, cardiovascular; HF, heart failure; LV, left ventricle; RV, right ventricle.
Figure 3 CAN-TREAT initial management algorithm for pa-
tients with newly identified heart failure and reduced ejection frac-
tion and atrial fibrillation. ACEi, angiotensin converting enzyme
inhibitors; ARB, angiotensin receptor blockers; CV, cardiovascular.
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absolute contraindication, and the NOACs are particularly attract-
ive due to lower rates of intracranial haemorrhage compared to
VKA therapy.33
Guideline-recommended heart failure and
reduced ejection fraction therapy
Achieving euvolaemia and the resolution of HF symptoms using
loop and thiazide diuretics are an important first step in the manage-
ment of all HF patients, regardless of heart rhythm.
Activation of neurohormonal pathways and RAAS are well de-
scribed in HF, and the majority of evidence-based therapies target
these compensatory mechanisms.41 Angiotensin converting enzyme
inhibitors have proven efficacy in HFrEF for significant reduction in
mortality, sudden cardiac death, and HF hospitalization,42 but no
trials have examined their benefit in concomitant AF. Angiotensin
receptor blockers are recommended as alternatives to ACEi in
cases of intolerance, and there are numerous RCTs supporting their
use in HFrEF.41 In CHARM, randomization to candesartan signifi-
cantly reduced CV death or HF hospitalization in HFrEF patients
with concomitant AF (HR 0.83; 95% CI 0.69–0.99), similar to that
observed in patients without AF at baseline (HR 0.84; 95% 0.77–
0.92).43 In contrast, irbesartan did not reduce the composite out-
come of hospitalization due to HF, stroke, myocardial infarction,
or death from vascular causes in AF patients enrolled in the Atrial
Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vas-
cular Events A or W trials. For those with a history of HF, the HR
was 0.90 comparing irbesartan to placebo (95% CI 0.75–1.08).44
It should be pointed out that both of these results were post hoc
defined sub-group analyses.
b-Blockers are now a standardized part of treatment in HFrEF
following numerous RCTs describing a substantial reduction in
all-cause mortality, CV death and hospitalization compared with
placebo. In these trials, between 8 and 23% of enrolled participants
were in AF at baseline.14 Pooling individual patient data from 11
RCTs (with 96% of recruited participants ever enrolled in such
trials), the adjusted HR for all-cause mortality for b-blockers vs. pla-
cebo was 0.73 (95% CI 0.67–0.80) in sinus rhythm. In patients with
AF the HR was 0.97 (95% CI 0.83–1.14), with the interaction
P-value for baseline rhythm highly significant at 0.002 with no het-
erogeneity (see Figure 4).14 The lack of benefit in AF was consistent
across all sub-groups, including age categories, gender, NYHA class,
and baseline heart rate. There were also no significant reductions in
a range of secondary outcomes despite a sample size of over 3000
patients, including CV hospitalization and composite clinical out-
comes.14 Again, these data are based on sub-group analysis and
the patients with AF differed to those in sinus rhythm. However,
pooling individual patient data allows more robust handling and stat-
istical analysis, as well as sufficient power.45 Hence clinicians should
not expect a prognostic benefit from b-blockers in HFrEF patients
with concomitant AF; however, there was no apparent harm and
patients may have other indications, such as symptom or heart
rate control. We are currently exploring whether this variance in
efficacy is due to heart rate, LVEF, or other fundamental differences
in how AF patients respond to b-blockers.46
Mineralocorticoid receptor antagonists (MRAs), such as spirono-
lactone and eplerenone, are recommended in all HFrEF patients
with persisting symptoms (NYHA classes II – IV) after treatment
with ACEi and b-blockers.41 Although the majority of data on
MRA are positive, in a post hoc analysis of the Atrial Fibrillation
and Congestive Heart Failure (AF-CHF) trial evaluating rate and
rhythm-control strategies, spironolactone was associated with in-
creased mortality (HR 1.4, 95% CI 1.1–1.8).47 Despite a propensity-
matched statistical model, it is not possible to exclude residual con-
founding as an explanation for this unexpected finding (i.e. sicker
Figure 4 b-Blockers in heart failure and reduced ejection fraction with sinus rhythm and atrial fibrillation. Kaplan–Meier survival curves for
b-blocker vs. placebo in heart failure patients with (A) sinus rhythm and (B) atrial fibrillation. Data are unadjusted survival curves for all reported
deaths. Hazard ratios are derived from an adjusted one-stage Cox regression model, stratified by study and censored at 1200 days (3.3 years).
Reproduced from Kotecha et al.14
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patients receiving MRA). Baseline AF was not reported in the Ran-
domized Aldactone Evaluation Study of spironolactone vs. pla-
cebo.48 In the Eplerenone in Mild Patients Hospitalization and
Survival Study in Heart Failure trial, the reduction in CV death or
HF hospitalization was similar for HFrEF patients with or without
a history of AF (P for interaction 0.59).49
To summarize, there are scarce data on the efficacy of ACEi, ARBs,
or MRA in HFrEF with concomitant AF to decrease morbidity or
mortality; however, their use is still recommended to reduce adverse
remodelling in HF. The totality of RCT data on b-blockers in HFrEF
patients with AF have now been analysed, and suggest thatb-blockers
have a neutral effect on death and hospitalization in these patients.
Rate vs. rhythm control of atrial
fibrillation
Although sub-group data suggest that sinus rhythm is associated with
improved outcomes in patients with AF (including all-cause sur-
vival),50 clinical trials have failed to demonstrate superiority of either
a rate or rhythm-control strategy. For example in the AF-CHF trial,
there was no difference in CV death when comparing a rate vs.
rhythm-control strategy in patients with HFrEF and NYHA classes
II– IV (HR 1.06, 95% CI 0.86–1.30, P ¼ 0.59), with similar findings
for all-cause mortality and worsening HF.51 There are several reasons
that rhythm control has failed to improve survival in clinical trials, in-
cluding limited efficacy and adverse effects of available treatments, or
delayed intervention such that the cumulative effects of AF are al-
ready unable to be reversed. Sinus rhythm can be difficult to achieve
and maintain, particularly in patients with HF. In the rhythm control
arm of AF-CHF, 21% crossed over to rate control, 82% were taking
amiodarone, 27%were in AF at 4-year follow-up, and 58% had at least
one episode of AF during the trial.51 On the other hand, in studies of
catheter ablation of AF, restoration of sinus rhythm is associated with
significant improvement in left ventricular function (11% increase in
LVEF on average).52 While there are no clear differences in CV out-
comes, patients with AF and HF who spend a higher proportion of
time in sinus rhythm suffer less severe functional impairment
(NYHA class III symptoms in 27 vs. 35%, P, 0.0001).53 Based on
these and other data, current guidelines reserve rhythm-control ther-
apy for those patients who experience AF-related symptoms or
worsening HF despite adequate rate control.54
Specific rate-control therapies
The three available therapies for rate control of AF in the context of
HFrEF are discussed below and summarized in Table 1.
b-Blockers
As previously discussed, b-blockers in HFrEF patients with AF do not
appear to improve mortality or reduce hospital admissions.14 How-
ever, their use is widespread for control of heart rate in AF, both
acutely and for long-term management. In the acute setting of HF
with rapid AF, b-blockers are useful for rate-reduction and preferred
to digoxin due to their effectiveness at high sympathetic tone.59 As
b-blockers can initially be negatively inotropic, initiation ofb-blockers
requires a measured approach using incremental dosage to achieve a
heart rate that balances the need for rate control with other haemo-
dynamic parameters. For long-term control of heart rate, b-blockers
are traditionally the first-line choice for clinicians.60
Digoxin
Cardiac glycosides, such as digoxin and digitoxin, have seen recent de-
clines in use after the publication of the DIG trial which showed no
mortality benefit from digoxin in HF patients with sinus rhythm.61,62
Importantly, patients randomized to digoxin suffered less hospitaliza-
tions. In observational studies and post hoc analysis of RCTs, there
have been concerns about increased mortality with digoxin,63 but
equally a number of studies have found no association.64–67 As clearly
demonstrated in a systematic review of all digoxin vs. control studies,
the main problem with non-randomized assessment is that clinicians
are more likely to prescribe digoxin to the sickest patients with HF
and/or AF, which results in bias that cannot be adjusted for, even
with complex statistical modelling.55 Unfortunately, there are cur-
rently no direct RCT comparisons of digoxin use in patients with
AF. Until further evidence becomes available, digoxin should be
used cautiously in appropriate patients, with no expectation of any ef-
fect on mortality.55 In a crossover mechanistic RCT of 47 patients
with HFrEF and AF, there were no differences in heart rate, blood
pressure, walk distance, or LVEF comparing carvedilol and digoxin, al-
though b-blockers did result in higher BNP levels (183 pg/mL with
carvedilol vs. 79.5 with digoxin; P ¼ 0.03). There was a small and mar-
ginally significant improvement in LVEF with combination b-blocker/
digoxin compared with placebo/digoxin after 4 months of treatment
(30.6+9.6% vs. 26.0+12.4%; P ¼ 0.048).56
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Rate control of atrial fibrillation in heart failure with reduced ejection fraction
Guidelines Agent Safety Efficacy
Recommended b-Blockers Individual patient data sub-group meta-analysis of
RCTs suggests no safety concerns.14
Individual patient data sub-group
meta-analysis of RCTs shows no impact on
mortality or hospitalization in concomitant
HFrEF and AF.14
Recommended as
second line
Digoxin Systematic review suggests no increase in mortality
in concomitant HF and AF; higher mortality in AF
patients in observational studies is likely due to
residual confounding.55
No RCTs vs. placebo in AF patients;55
combined therapy with b-blockers
improves LVEF.56
Avoid/use caution Non-dihydropyridine
calcium channel blockers
Limited sub-group data in post-MI patients only;
suggestive of increased death, re-infarction, and
HF.57
None demonstrated.58
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Calcium channel blockers
Non-dihydropyridine calcium channel blockers (verapamil or diltia-
zem) are not recommended in patients with significantly impaired
left ventricular function due to their negative inotropic effects,
although specific data are limited.41,68 In the Multicenter Diltiazem
Postinfarction Trial, patients were randomized to diltiazem or
placebo 3–15 days after the onset of myocardial infarction.69 HF
patients, including 490 with evidence of pulmonary congestion,
had an increase in the composite of cardiac death or non-fatal
re-infarction (HR 1.41, 95% CI 1.01–1.96). In subsequent analysis,
diltiazem was found to increase late-onset HF in those with LVEF
,40%.57 Verapamil did not improve outcomes after myocardial
infarction in patients who developed HF in the Danish Verapamil
Infarction Trials.58
Heart rate targets for atrial fibrillation in the context
of heart failure and reduced ejection fraction
Following the publication of the Rate Control Efficacy in Permanent
Atrial Fibrillation (RACE II) trial, patients with AF can initially be
treated to a more lenient heart rate regime (,110 beats/min resting
heart rate). To summarize, 614 patients with permanent AF were
randomized to a heart rate,80 b.p.m. at rest and,110 b.p.m. dur-
ing moderate exercise or lenient control, with results showing a
similar rate of composite clinical events in each arm.70 There
were also no differences in functional outcomes, hospital admis-
sions, or symptoms.71 Fifteen percent of the population had LVEF
,40% but it remains unclear if these targets apply to AF patients
with HFrEF. However, these findings are consistent with other re-
sults14,72,73 and would suggest that heart rate in AF is more a marker
of disease than a therapeutic target and that a lenient heart rate may
be acceptable if symptoms are controlled and tachycardia is avoided.
It is worth noting that other guideline recommendations continue to
advocate a resting heart rate ,80 b.p.m. in patients with symptom-
atic AF and left ventricular dysfunction.74
Specific rhythm-control strategies
Cardioversion
The first step in rhythm control is the restoration of sinus rhythm,
which often requires cardioversion. Urgent cardioversion is recom-
mended in any patient with significant haemodynamic impairment
secondary to AF. Elective cardioversion is indicated in individuals
with symptomatic persistent AF. Unfortunately, recurrence of AF
after successful cardioversion is a frequent problem (50% at 6
months), particularly in patients with HF.75,76 Over half of inpatients
undergoing cardioversion for atrial arrhythmias have HF.77
Antiarrhythmic drugs
Antiarrhythmic drugs (AAD) for the maintenance of sinus rhythm in
patients with AF and HFrEF are limited to dofetilide or amiodarone;
however, dofetilide is not approved in Europe. Both drugs have as-
sociated safety concerns (see Table 2). Other AAD are not recom-
mended for general use in HFrEF.When antiarrhythmic medications
are used to treat AF in patients with HF, every effort should bemade
to avoid toxicity.
Catheter ablation
Catheter ablation has been shown to significantly improve freedom
fromAF in patients who have failed AAD,86 and avoids their toxicity.
Accordingly, the use of catheter ablation has increased in clinical
practice.87 Observational data suggest that in patients with AF and
HF, LVEF improves by 11.1% after ablation (95% CI 7.1–15.2).52
Higher recurrence rates of AF are seen after ablation in patients
with HF,88 leading to a need for additional ablation procedures.89,90
The PABA-CHF pilot study compared a rate-control approach with
atrioventricular (AV) node ablation and cardiac resynchronization
therapy (CRT), vs. catheter ablation in 81 patients with
drug-refractory AF and mild-to-moderate HF.91 In the ablation
group, 71% maintained sinus rhythm without AAD. The patients
randomized to ablation had better HF-related quality of life, better
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Antiarrhythmic drug therapy for atrial fibrillation in heart failure
Guidelines Agent Class Safety Efficacy
Recommended Amiodarone Mixed channel
blockade
Risks of toxicity, including thyroid, hepatic,
pulmonary, and neurological.78
Superior efficacy for maintenance of sinus rhythm vs.
placebo: odds ratio 0.15 (95% CI 0.10–0.22).79
Dofetilide III Requires inpatient stay for loading. Risk of
torsades 0.8–3.3%. Not approved in EU.
Lower risk of all-cause rehospitalization in patients
with AF at baseline vs. placebo: relative risk 0.70
(95% CI 0.56–0.89).80
Caution
required
Dronedarone Mixed channel
blockade
Increased mortality in patients with HF and
permanent AF.15,81
Decreased risk of CV hospitalization or death in
patients with AF and no recent HF
decompensation vs. placebo: 0.76 (95% CI
0.69–0.84).82
Sotalol III Concern for excess proarrhythmia in
patients with acute myocardial infarction
or LVEF ≤40%: relative risk 1.65 (95% CI
1.15–2.36) for all-cause mortality.83a
Sotalol was inferior to amiodarone in patients with
AF (28% had NYHA class I/II HF).84
Contraindicated Flecainide and
Propafenone
I Flecainide, encainide and moracizine
increased mortality in patients with
myocardial infarction.85 Propafenone can
precipitate decompensated HF,
particularly in CYP 2D6
slow-metabolizers.
aSWORD evaluated D-sotalol rather than D,L-sotalol.
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6-min walk times, and greater improvement in LVEF. Similar findings
were reported in the ARC-HF trial of 52 HFrEF patients randomized
to ablation or rate control with b-blockers/digoxin.92 More recent-
ly, pre-publication results from the Ablation vs. Amiodarone for
Treatment of Atrial Fibrillation in Patients with Congestive Heart
Failure and an Implanted ICD/CRTD trial suggest promising results
for catheter ablation in this patient group, including greater mainten-
ance of sinus rhythm.93 While there is debate as to which ablative
approach is most effective for restoring sinus rhythm in patients
with persistent forms of AF, the Substrate and Trigger Ablation
for Reduction of Atrial Fibrillation Trial Part II demonstrated that
neither additional linear ablation nor ablation of complex fractio-
nated electrograms improves efficacy.94 Larger, more definitive
trials are underway to help clarify whether ablation leads to im-
proved CV outcomes in patients with AF and HF.
Recognizing the limitations of percutaneous ablation in patients
with more advanced forms of AF, there are emerging alternative ap-
proaches to catheter ablation, including both surgical ablation and
hybrid ablation. In the ‘convergent’ procedure, a surgical transdiaph-
ragmatic endoscopic approach is used to make non-contiguous epi-
cardial ablation lesions. These lesions are later completed with
catheter ablation to produce complete pulmonary vein isolation.
In one study of 101 patients, in which 30% had symptomatic HF,
freedom from AF was 66% at 1 year with a major complication
rate of 6%.95 More traditional surgical ablation, like the Cox-Maze
procedure, also has a role, particularly when HF patients with symp-
tomatic AF are undergoing surgery for valvular disease or revascu-
larization.96 Preliminary data in patients with concomitant HF
suggests that Cox-Maze procedures may be effective and safe in
those with LVEF ,40% and symptomatic HF, with sinus rhythm
maintained in .80% at 6-month follow-up.97
Device therapy and management
of advanced heart failure
Cardiac resynchronization therapy decreases mortality and pre-
vents hospitalizations in patients with symptomatic HF, LVEF
≤35%, and QRS duration ≥120 ms.98 Between 25 and 50% of
patients eligible for CRT have AF, although patients with AF are
not well represented in randomized trials of CRT.99 At present,
CRT is a class IIa recommended therapy in patients with HF and
concomitant AF.100,101 Loss of AV synchrony and rapid ventricular
rates in AF may impair benefit from CRT and small studies have sug-
gested that the beneficial effect is rather due to AV node abla-
tion.102,103 A meta-analysis of 23 observational studies including
7495 recipients suggests that patients with AF have a higher rate
of non-response to CRT (35 vs. 28%, P ¼ 0.001).102 Recent data
from 8951 patients with AF and HF in the US NCDR registry de-
monstrated that CRT-D therapy was associated with lower mortal-
ity, all-cause, and HF readmissions compared with ICD therapy
alone.104 Thus while response rates are lower in patients with AF,
CRT should still be pursued in appropriate patients and every
attempt should be made to ensure aggressive rate control. This is
important to ensure biventricular pacing is as close to 100% as pos-
sible105,106 and avoid inappropriate shocks. AV node ablation
should be considered in cases of tachycardia refractory to medical
therapy.
Patients with HFrEF and AF often present unique challenges when
implanted pump-support is required. Increased hospitalization and
mortality have been observed in patients with the HeartMate II
left ventricular assist device (adjusted HR for persistent AF 3.54;
95% CI 1.52–8.25; P, 0.01), with more frequent thromboembolic
events in AF despite higher INR.107
Tachycardiomyopathy
Tachycardia-induced cardiomyopathy is a long-recognized compli-
cation of AF, affecting as few as 3% and as many as 25% of patients
with atrial tachyarrhythmias.25,108 Several mechanisms have been
proposed to contribute to tachycardia-induced cardiomyopathy,
including decreased density of L-type calcium channels and
b-adrenergic receptors, increased intracellular calcium and diastolic
contracture, impaired myocardial blood flow due to raised left ven-
tricular diastolic pressure, oxidative stress, and even deleterious
polymorphisms in angiotensin converting enzyme.109
The diagnosis should be considered in a patient with no prior CV
history who presents with new-onset HF in the setting of AF with
rapid ventricular conduction. When evaluating patients with AF
and left ventricular dysfunction, it is paramount to exclude other
underlying causes of ventricular dysfunction, including ischaemia.
Once ischaemia has been ruled out, other indicators of non-
ischaemic cardiomyopathy should also assessed (e.g. left ventricular
hypertrophy, alcohol/drug use, infiltrative disorders, etc.). It is im-
portant to emphasize that there are no established diagnostic cri-
teria for tachycardia-induced cardiomyopathy and the diagnosis
can be elusive in the majority of patients with established CV disease
or when the initial presentation is missed.109
Once anticoagulation has been initiated and the risk of thrombus
has been addressed, sinus rhythm should be restored with cardio-
version. Several methods can be used to maintain sinus rhythm;
short-term amiodarone (3 months) is often helpful and allows for
recovery before deploying a more durable treatment modality
such as catheter ablation. Recovery of ventricular function confirms
the diagnosis and may take up to 6 weeks.110 Patients with
tachycardia-induced cardiomyopathy have similar outcomes follow-
ing catheter ablation compared with patients without structural
heart disease.111
Heart failure with preserved
ejection fraction and atrial
fibrillation
Heart failure with preserved ejection fraction is common, respon-
sible for over half of prevalent HF, yet no therapies have yet been
shown to reduce mortality or morbidity.41 Atrial fibrillation and
HFpEF are closely linked, with similar risks and mechanisms as dis-
cussed above.112 Current management is no different to that in sinus
rhythm; diuretics to reduce signs and symptoms of fluid overload,
and optimisation of hypertension and other comorbidities.
Whether MRA have a specific role in improving exercise capacity
and diastolic function by reducing fibrosis is currently under inves-
tigation.113 The risk of stroke in AF with HFpEF is similar to HFrEF,
and therefore all suitable patients require anticoagulation.114
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Future directions
Given the limited treatment options for patients with HF and AF,
there is a clear unmet need in this important patient population.
Future investigation is particularly required for rate control, optimal
methods of rhythm control, and prevention. There is also a need to
stratify the use of various treatments to improve efficacy and safety,
and a number of studies are addressingwhether genetic profiling can
help to personalize our therapeutic approach.
Despite advances in many areas of AF, it seems that the evidence
to guide best practices for rate control is more uncertain than ever.
Adequately powered prospective clinical trials are needed to clarify
optimal rate-control targets and the best pharmacologic treatments
to achieve rate control in patients with HF and AF. While ablation
represents a promising alternative to AAD, clinicians require
more information on the balance between effectiveness, complica-
tions, and potential prognostic benefits. Finally, given the poor out-
comes observed in patients with HF and AF, perhaps the best
treatment strategy is to prevent AF from occurring in the first place.
Clinical trials of interventions targeted at left atrial substrate and
preventing disease progression may have an important role in this
regard. Table 3 presents some of the main studies currently recruit-
ing that will assess patients with HF and AF. It is clear that the com-
bination of these two common CV conditions will continue to
challenge physicians both in CV and general medicine for many years
to come.
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